Skip to content

US · INO · BIOTECHNOLOGY

Inovio Pharmaceuticals, Inc. (INO) intrinsic value and stock valuation

$1.76as of 2026-11-21 · Mkt cap 46.78M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Inovio Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values INO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from INO’s statements →

Inovio Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Plymouth Meeting, PA 19462 inovio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$70K-60.6% 5y CAGRd
20112025
Net income
-$-84.95M
20112025
Free cash flow
-$-88.92M
20112025
Total equity
$24.1M-44.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$70K$220K$830K$10.3M$1.77M
Operating income-$-86.82M-$-112.4M-$-143.94M-$-267.57M-$-301.22M
Net income-$-84.95M-$-107.25M-$-135.12M-$-279.82M-$-303.66M
EPSd-$-1.81M-$-3.95M-$-6.09M-$-14.07M-$-17.45M
Operating cash flow-$-88.63M-$-104.08M-$-124.37M-$-216.22M-$-215.71M
Capital expenditure-$-290K-$-490K-$-320K-$-970K-$-1.23M
Free cash flow-$-88.92M-$-104.56M-$-124.69M-$-217.18M-$-216.94M
Total assets$74.3M$113.2M$171M$348.5M$495.9M
Total debt$9.37M$11.9M$30.2M$32.1M$33M
Net debt-$-34.91M-$-53.95M$15.9M-$-14.25M-$-38.12M
Total equity$24.1M$68.5M$117.4M$222.4M$399.7M
Cash and short-term investments$58.5M$94.1M$145.3M$253M$401.3M
Income statement
20252024202320222021
Revenue$70K$220K$830K$10.3M$1.77M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$70K$220K$830K$10.3M$1.77M
Research and development expenses$54.2M$75.6M$86.7M$187.7M$249.2M
Selling, general and administrative expenses$32.7M$37M$47.6M$90.2M$53.8M
Other expenses$0.00$0.00$10.5M$0.00$0.00
Operating expenses$86.9M$112.6M$144.8M$277.8M$303M
Cost and expenses$86.9M$112.6M$144.8M$277.8M$303M
Interest income$2.42M$4.77M$8.13M$4.78M$3.36M
Interest expense$0.00$180K$1.22M$1.25M$1.94M
Depreciation and amortization$2.99M$3.13M$3.5M$5.5M$4.73M
Ebitda-$-81.96M-$-103.95M-$-130.39M-$-270.9M-$-296.56M
Operating income-$-86.82M-$-112.4M-$-143.94M-$-267.57M-$-301.22M
Total other income/expenses, net$1.88M$5.14M$8.82M-$-12.24M-$-2.44M
Income before tax-$-84.95M-$-107.25M-$-135.12M-$-279.82M-$-303.66M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-84.95M-$-107.25M-$-135.12M-$-279.82M-$-303.66M
Weighted average shares outstanding$46.9M$27.2M$22.2M$19.9M$17.4M
Weighted average diluted shares outstanding$46.9M$27.2M$22.2M$19.9M$17.4M
Balance sheet
20252024202320222021
Cash and short-term investments$58.5M$94.1M$145.3M$253M$401.3M
Net receivables$0.00$1.2M$2.41M$11.7M$8.03M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$61.1M$97.8M$153.1M$315.2M$448.4M
Property, plant and equipment, net$9.07M$11.8M$14.5M$18M$29M
Goodwill and intangible assets$0.00$0.00$0.00$12.6M$13.1M
Long-term investments$2.1M$1.61M$2.78M$2.01M$3.91M
Total non-current assets$13.2M$15.4M$17.8M$33.3M$47.5M
Total assets$74.3M$113.2M$171M$348.5M$495.9M
Accounts payable$2.62M$6.44M$4.65M$21.1M$28M
Short-term debt$2.82M$2.5M$19.2M$2.8M$2.6M
Deferred revenue$0.00$0.00$0.00$0.00$20K
Total current liabilities$43.7M$35.3M$42.6M$96.9M$65.7M
Long-term debt$6.55M$9.37M$11M$29.3M$30.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$60K
Total non-current liabilities$6.55M$9.37M$11M$29.3M$30.5M
Capital lease obligations$9.37M$11.9M$13.4M$15.5M$18.1M
Total liabilities$50.2M$44.7M$53.6M$126.2M$96.3M
Common stock$70K$40K$20K$20K$220K
Retained earnings-$-1.82B-$-1.73B-$-1.62B-$-1.49B-$-1.21B
Accumulated other comprehensive income (loss)-$-640K-$-680K-$-660K-$-700K-$-280K
Total equity$24.1M$68.5M$117.4M$222.4M$399.7M
Total investments$16.3M$29.9M$133.8M$208.7M$334.1M
Total debt$9.37M$11.9M$30.2M$32.1M$33M
Net debt-$-34.91M-$-53.95M$15.9M-$-14.25M-$-38.12M
Cash flow statement
20252024202320222021
Net income-$-84.95M-$-107.25M-$-135.12M-$-279.82M-$-303.66M
Depreciation and amortization$2.99M$3.13M$3.5M$5.5M$4.73M
Stock-based compensation$3.76M$6.6M$11.1M$22.6M$26.3M
Change in working capital-$-9.22M-$-2.66M-$-10.26M$19.8M$50.4M
Accounts receivable$0.00$1.21M$9.33M-$-3.71M$11M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-6.42M-$-3.37M-$-45.99M$32.6M$26.1M
Net cash provided by operating activities-$-88.63M-$-104.08M-$-124.37M-$-216.22M-$-215.71M
Investments in property, plant and equipment-$-290K-$-490K-$-320K-$-970K-$-1.23M
Acquisitions, net$0.00$0.00$6.22M-$-2M$0.00
Net cash used for investing activities$14M$104.1M$87.4M$109.6M-$-175.34M
Common stock issued$53.2M$68.3M$5.46M$83M$209.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$53.1M$51.5M$5M$81.8M$211.5M
Net change in cash-$-21.54M$51.5M-$-32.02M-$-24.81M-$-179.58M
Cash at end of period$44.3M$65.8M$14.3M$46.3M$71.1M
Operating cash flow-$-88.63M-$-104.08M-$-124.37M-$-216.22M-$-215.71M
Capital expenditure-$-290K-$-490K-$-320K-$-970K-$-1.23M
Free cash flow-$-88.92M-$-104.56M-$-124.69M-$-217.18M-$-216.94M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Inovio Pharmaceuticals, Inc.

        Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

        CEO
        Jacqueline E. Shea
        Employees
        112
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Inovio Pharmaceuticals, Inc. (INO)?

        Inovio Pharmaceuticals, Inc. (INO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INO undervalued?

        INO trades at a price of $1.76 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.